Finnish biotechnology firm FIT Biotech focused in the development and commercialization of its Gene Transport Unit (GTU) technology and GTU product applications in DNA vaccination as well as in immuno – and gene therapies, has developed a new vaccine for the treatment of HIV. A trial will start after spring 2014 with the aim of evaluate the new vaccine’s efficacy at reducing the viral load of current HIV patients, in combination with AIDS medication. The vaccine is expected to have the ability to stop HIV infection from progressing dead in its tracks, or even help patients free their bodies of the infection completely. The study will include more than 1,000 patients and will take two to three years. If the study will fit the endpoint prefixed, FDA and EMA authorizations will be required.